CC

Rating neutralAI MemoPost-earnings T+3

Chemours

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 normalization after Washington Works outage and seasonal TSS ramp [#8-K-2026-05-05] • 2026-08-06

Expected move: -5%

Biggest risk

The print still carried a revenue miss and weak segment quality outside TSS. MarketBeat reported Q1 EPS of $0.05 versus a -$0.05 consensus but revenue of $1.38 billion versus $1.40 billion expected, while TT and APM remained the clear drags. The stock reaction suggests investors focused more on weak TT/APM margins, leverage, and execution risk than on the EPS beat.

Invalidation

Break below $17 or thesis failure.

What would change my mind?

Primary-source earnings showed stronger-than-feared consolidated EBITDA at $169 million with TSS posting record first-quarter results, plus Q2 and FY2026 guidance that implies a meaningful sequential recovery [#8-K-2026-05-05]. Secondary follow-through was not uniformly negative: Mizuho raised its price target to $30 from $25 and kept Outperform, while Truist raised its target to $30 from $27 and kept Buy.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$22

p=0%

Bull target

$28

p=0%

Bear target

$17

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

TT and APM weakness can keep the stock in penalty box
FY2026 deleveraging path depends on TT pricing, TSS demand, and Kuan Yin cash proceeds [#8-K-2026-05-05]
Primary-source earnings showed stronger-than-feared consolidated EBITDA at $169 million with TSS posting record first-quarter results, plus Q2 and FY2026 guidance that implies a meaningful sequential recovery [#8-K-2026-05-05].

BearKey bullets

APM recovery is not yet proven: Q1 APM adjusted EBITDA fell 84% to $5 million, and management said the Washington Works outage plus related costs hurt the quarter by about $25 million [#8-K-2026-05-05].
Balance-sheet risk is still material: net leverage was about 4.9x at March 31, 2026, so the year-end deleveraging goal requires both EBITDA delivery and further debt reduction [#8-K-2026-05-05].
Legacy environmental and litigation cash uses remain an overhang; Chemours disclosed about $53 million of restricted cash tied mainly to MOU-related escrow payments involving DuPont, Corteva, and EID [#8-K-2026-05-05].

WatchKey bullets

Q2 normalization after Washington Works outage and seasonal TSS ramp [#8-K-2026-05-05]

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $22 (p=0%)

Bull/Bear spread: +20% / -27%

Vs latest close: Bull +20% · Base -5% · Bear -27%

Scenario probabilities

Bull Target: $28 (p=0%)Base Target: $22 (p=0%)Bear Target: $17 (p=0%)

Commentary

Post-earnings sentiment is mixed and still fragile. On May 5, 2026, CC closed at $27.94; on May 6 it fell 15.28% to $23.67, and by the May 7 anchor it had fallen to $22.41. That negative reaction came even though MarketBeat showed an EPS beat and even though Mizuho and Truist both raised targets after the print, implying investors are prioritizing the revenue miss and weak TT/APM execution over the guidance reaffirmation. Social coverage was not provided in the packet, so this remains a monitoring-style view rather than a high-conviction turn call.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

TT and APM weakness can keep the stock in penalty box
FY2026 deleveraging path depends on TT pricing, TSS demand, and Kuan Yin cash proceeds [#8-K-2026-05-05]

Scenarios

Bull Target (Scenario probability)

$28 / p=0% prob

Base Target (Scenario probability)

$22 / p=0% prob

Bear Target (Scenario probability)

$17 / p=0% prob

Price $23 as of 2026-06-02

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +20% · Base -5% · Bear -27%

Sentiment & Exposure

News Sentiment (30d)

0.05

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 normalization after Washington Works outage and seasonal TSS ramp [#8-K-2026-05-05]
Chemours guided Q2 2026 consolidated adjusted EBITDA to $220 million-$250 million, with APM expected at $12 million-$18 million as Washington Works returns toward normal operations and TSS benefits from seasonal refrigerant demand; a clean delivery would test whether the post-earnings selloff was overdone.
Prob 65.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

TT and APM weakness can keep the stock in penalty box
2026-08-06
Q1 TT adjusted EBITDA fell 64% year over year to $18 million and APM adjusted EBITDA fell 84% to $5 million, with weak cyclical end markets, unfavorable ore mix, mining-footprint changes, and outage-related costs offsetting the stronger TSS result [#8-K-2026-05-05]. If Q2 recovery slips, the market may keep discounting the equity despite higher full-year guidance.
Prob 40% • Move -15% • Priced-in 55%

Long-term Catalysts

Months to a year

FY2026 deleveraging path depends on TT pricing, TSS demand, and Kuan Yin cash proceeds [#8-K-2026-05-05]
2027-05-08
Management reiterated FY2026 net sales growth of 3%-5%, adjusted EBITDA of $800 million-$900 million, free-cash-flow conversion above 20%, and net leverage below 3.8x by year-end; April receipt of about $287 million from the Kuan Yin land sale and partial euro term-loan repayment support the balance-sheet story if operating delivery holds.
Prob 55% • Move 18% • Priced-in 35%

Risks

APM recovery is not yet proven: Q1 APM adjusted EBITDA fell 84% to $5 million, and management said the Washington Works outage plus related costs hurt the quarter by about $25 million [#8-K-2026-05-05].
Balance-sheet risk is still material: net leverage was about 4.9x at March 31, 2026, so the year-end deleveraging goal requires both EBITDA delivery and further debt reduction [#8-K-2026-05-05].
Legacy environmental and litigation cash uses remain an overhang; Chemours disclosed about $53 million of restricted cash tied mainly to MOU-related escrow payments involving DuPont, Corteva, and EID [#8-K-2026-05-05].
TT volume and mix remain weak: Q1 TT net sales fell 6% and adjusted EBITDA fell 64% year over year to $18 million, with margin down to 3% [#8-K-2026-05-05].

Peers

Symbol	Summary
TROX	Useful titanium-dioxide read-through for TT pricing and margin recovery; more direct than the packet's size-matched materials comps.
ASIX	A closer U.S. chemicals comp for cyclical industrial demand and cost discipline, though still not a clean match for Chemours' refrigerants-plus-TiO2 mix.
HUN	Diversified chemicals peer that helps frame broader volume and margin pressure across cyclical end markets, but peer fit remains loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: CC - Chemours - RankAlpha